Abstract
Primaquine, an antimalarial drug, is essential for preventing relapses
of Plasmodium vivax. However, it poses a risk of hemolytic anemia,
particularly in glucose-6-phosphate dehydrogenase (G6PD) deficient
patients. This case report details a 27-year-old male with normal G6PD
levels who developed hemolytic anemia following primaquine therapy for
P. vivax malaria. Despite a normal quantitative G6PD analysis, the
patient experienced a significant drop in hemoglobin, necessitating
early discontinuation of the drug. This case highlights the potential
for hemolysis in G6PD-normal patients, underscoring the importance of
close monitoring and the limitations of current G6PD screening methods.